- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06131554
A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years
May 6, 2024 updated by: CanSino Biologics Inc.
A Multicenter, Randomized, Double-blinded, Positive-controlled Phase Ⅲ Clinical Trial to Evaluate Lot-to-lot Consistency, Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years
This is a multicenter, randomized, double-blinded, positive controlled study to evaluate the lot-to-lot consistency, immunogenicity and safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in adults aged 18 to 55 years.
Subjects will be randomized to receive investigational Lot 1, Lot 2, Lot 3 vaccine or control vaccine in a 1:1:1:1 ratio, with the subjects in experimental group randomly and equally assigned to three different batches of MCV4 for single-dose vaccination.
Study Overview
Status
Recruiting
Conditions
Study Type
Interventional
Enrollment (Estimated)
1480
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Lina Wang
- Phone Number: 022-58213600-6051
- Email: lina.wang@cansinotech.com
Study Locations
-
-
-
Surabaya, Indonesia, 60131
- Recruiting
- Husada Utama Hospital
-
Contact:
- Isti Suharjanti
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Participants aged 18-55 years old at the time of screening, who are in good health condition as determined by the study clinician.
- Participants who have not been vaccinated with any meningococcal vaccines (including but not limited to meningococcal group A and C conjugate vaccine, meningococcal group A and C polysaccharide vaccine, Group ACYW135 Meningococcal polysaccharide/conjugate vaccine).
- The participant or participant's legal guardian signs the informed consent form (ICF) and participant agrees to comply with the requirements of protocol and finish the 1-year follow-up.
- Participants who are willing to discuss medical history with investigators or doctors and allow access to all medical records relevant to this trial.
Participants with child-bearing potential who are willing to practice adequate contraception methods from signing the ICF to 12 months after vaccination. This includes:
- Abstinence from penile-vaginal intercourse,
- Hormonal contraceptives such as oral contraceptives (the pill), injectables, implants, patches or estrogen vaginal ring (a ring-shaped hormonal contraceptive device that is used inside the vagina),
- Intrauterine device (IUD/Spiral),
- Male partner sterilization (vasectomy) prior to the female subject's entry into the study, and this male is the sole partner for that subject,
- Male condom combined with a vaginal spermicide (a substance that can kill the sperm cells inside the vagina) or female diaphragm, whether with or without a vaginal spermicide .
- Be able to communicate well with the investigator, and to understand and comply with the requirements of this clinical trial.
Exclusion Criteria:
- Axillary temperature >37.5°C (99°F).
- Have congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.
- A history of epilepsy, convulsions or history/family history of mental illness.
- Have meningitis or a history of meningitis illness.
- Positive result of urine pregnancy test (also required for women within one year of menopause), lactating women, or participant /his partner is planning to become pregnant within 1 year.
- Hypersensitivity to a component or excipient of the vaccine used in this clinical trial (mainly: group A, C, Y or W135 meningococcal capsular polysaccharide, diphtheria toxoid or diphtheria antigen, sucrose, mannitol, sodium chloride, dipotassium hydrogen phosphate trihydrate, potassium dihydrogen phosphate).
- In the past 6 months (internal time < 6 months), participants have received immunosuppressive treatment, cytotoxic treatment, glucocorticoid treatment, etc. (excluding local treatment, surface treatment of acute non-concurrent dermatitis, spray treatment of allergic rhinitis).
- Received or plan to receive blood/plasma products or immunoglobulins throughout the study period or 60 days prior to study vaccination.
- Use of non-prescription drugs such as antipyretic (e.g., acetaminophen) and anti-inflammatory drugs (e.g., ibuprofen, naproxen etc.) within 12 hours before the administration of vaccine.
- Have severe hypertension that is not controlled by medication (at the time of field measurement: systolic blood pressure ≥ 160 mmHg and diastolic blood pressure ≥ 100 mmHg).
- Suffering from a severe chronic disease or a condition that is in a progressive stage and cannot be well controlled, such as thyroid disease
- Participants with known or suspected diseases that are judged by the investigator to affect the vaccination assessment, for example, acute infectious diseases, severe respiratory disease, severe cardiovascular disease, severe allergic skin disease etc.
- History of serious adverse reactions associated with the vaccine and/or history of severe allergic reactions (e.g., systemic allergic reactions) to any component of the study vaccine.
- Immunocompromised individuals with known or suspected immunodeficiency as determined by medical history and/or physical examination (e.g., HIV infection, history of pancreatic, liver, spleen, kidney disease or history of resection).
- Positive for HIV, Hepatitis B, Hepatitis C or Syphilis.
- Bleeding constitution or condition associated with prolonged bleeding for which intramuscular injection is contraindicated in the opinion of the investigator.
- Administration of live attenuated vaccine within 14 days or other vaccines within 7 days.
- Participation in other studies involving interventional studies within 28 days prior to screening and/or during study participation.
- According to the judgment of the investigator, participants could be excluded due to various medical, psychological, social or other conditions that are contrary to the trial protocol or that affect the subject's ability to sign informed consent.
- Investigator site staff directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members,sponsor staff and their respective family members.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: batch 1 of MCV4
1 dose of Menhycia on Day 0
|
1 dose of Menhycia (0.5ml) on Day 0, Intramuscular injection
Other Names:
|
Experimental: batch 2 of MCV4
1 dose of Menhycia on Day 0
|
1 dose of Menhycia (0.5ml) on Day 0, Intramuscular injection
Other Names:
|
Experimental: batch 3 of MCV4
1 dose of Menhycia on Day 0
|
1 dose of Menhycia (0.5ml) on Day 0, Intramuscular injection
Other Names:
|
Active Comparator: Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
1 dose of Menactra on Day 0
|
1 dose of Menactra (0.5ml) on Day 0, Intramuscular injection
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The geometric mean titer (GMT) of serogroup A, C, Y and W135 meningococcal rSBA titer in all participants.
Time Frame: Day 30 post vaccination
|
Day 30 post vaccination
|
The seroconversion rate of serogroup A, C, Y, and W135 meningococcal rSBA titer.
Time Frame: Day 30 post vaccination
|
Day 30 post vaccination
|
The incidence of adverse reactions (ARs) in all participants.
Time Frame: Within 7 days post vaccination
|
Within 7 days post vaccination
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The geometric mean fold increase (GMI) of serogroup A, C, Y and W135 meningococcal rSBA titer in all participants.
Time Frame: Day 30 post vaccination
|
Day 30 post vaccination
|
The proportion of GMT ≥ 1:128 of serogroup A, C, Y and W135 meningococcal rSBA titer on day 30 post vaccination in all participants.
Time Frame: Day 30 post vaccination
|
Day 30 post vaccination
|
The incidence of ARs and adverse events (AEs) in all participants.
Time Frame: Within 30 days post vaccination
|
Within 30 days post vaccination
|
The incidence of ARs in all participants.
Time Frame: Within 30 min post vaccination
|
Within 30 min post vaccination
|
The incidence of serious adverse events (SAEs) in all participants.
Time Frame: Within 365 days post vaccination
|
Within 365 days post vaccination
|
The GMT of serogroup A, C, Y and W135 meningococcal antibodies in the 480 subjects (120 of each subgroup,Immunopersistence group)
Time Frame: Day 90, day 180 and day 365 post vaccination
|
Day 90, day 180 and day 365 post vaccination
|
The GMI of serogroup A, C, Y and W135 meningococcal antibodies in the 480 subjects (120 of each subgroup,Immunopersistence group).
Time Frame: Day 90, day 180 and day 365 post vaccination
|
Day 90, day 180 and day 365 post vaccination
|
The proportion of GMT ≥ 1:128 of serogroup A, C, Y and W135 meningococcal antibodies in the 480 subjects (120 of each subgroup,Immunopersistence group).
Time Frame: Day 90, day 180 and day 365 post vaccination
|
Day 90, day 180 and day 365 post vaccination
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Isti Suharjanti, Dr, Husada Utama Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 20, 2024
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
November 9, 2023
First Submitted That Met QC Criteria
November 13, 2023
First Posted (Actual)
November 14, 2023
Study Record Updates
Last Update Posted (Actual)
May 8, 2024
Last Update Submitted That Met QC Criteria
May 6, 2024
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- Infections
- Central Nervous System Infections
- Gram-Negative Bacterial Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Meningitis, Bacterial
- Central Nervous System Bacterial Infections
- Meningococcal Infections
- Neisseriaceae Infections
- Neuroinflammatory Diseases
- Meningitis, Meningococcal
- Meningitis
- Physiological Effects of Drugs
- Immunologic Factors
- Vaccines
Other Study ID Numbers
- CTP-MCVF-006
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Meningococcal Meningitis
-
Prof. Elizabeth MillerNovartis VaccinesCompletedMeningococcal Meningitis, Serogroup A | Meningococcal Meningitis, Serogroup B | Meningococcal Meningitis, Serogroup C | Meningococcal Meningitis, Serogroup Y | Meningococcal Meningitis, Serogroup WUnited Kingdom
-
Chiron CorporationUnknownMeningococcal Disease; Meningococcal MeningitisUnited Kingdom
-
Sanofi Pasteur, a Sanofi CompanyCompletedMeningitis | Meningococcal Infections | Meningococcal Meningitis | Invasive Meningococcal DiseaseUnited States
-
Novartis VaccinesCompletedMeningococcal Disease | Meningococcal MeningitisSpain, Italy, United Kingdom, Czech Republic
-
Novartis VaccinesCompletedMeningococcal Disease | Meningococcal MeningitisChile, Colombia, Panama
-
Novartis VaccinesCompletedMeningococcal Disease | Meningococcal MeningitisKorea, Republic of
-
Novartis VaccinesCompletedMeningococcal Disease | Meningococcal MeningitisUnited States, Canada
-
Novartis VaccinesNovartisCompletedMeningococcal Disease | Meningococcal MeningitisUnited States
-
NovartisNovartis VaccinesCompletedMeningococcal Disease | Meningococcal MeningitisAustralia, Canada
-
Novartis VaccinesCompletedMeningococcal Disease | Meningococcal MeningitisChile, Colombia, Panama
Clinical Trials on batch 1 of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4)
-
Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdActive, not recruiting
-
Walvax Biotechnology Co., Ltd.CompletedMeningococcal InfectionsChina
-
Beijing Minhai Biotechnology Co., LtdCompleted
-
Aimei Vacin BioPharm (Zhejiang) Co., Ltd.Not yet recruitingMeningococcal MeningitisChina
-
Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdActive, not recruitingMeningitis, MeningococcalChina
-
PfizerCompletedNeisseria Meningitidis (Bacterial Meningitis) | Invasive Pneumococcal Disease (IPD)Germany
-
Sanofi Pasteur, a Sanofi CompanyCompleted
-
Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdCompletedMeningitis, MeningococcalChina
-
Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdAir Force Military Medical University, China; Guangxi Center for Disease Control... and other collaboratorsUnknownMeningitis, MeningococcalChina
-
Sanofi Pasteur, a Sanofi CompanyCompletedMeningitis | Meningococcal Infections | Meningococcal MeningitisUnited States, Puerto Rico